NASDAQ · MOLN
Healthcare · Biotechnology
$3.58
Up+$0.05 (+1.42%)
Updated Nov 1, 2026, 9:21 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MOLN
1M range · 18 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
MOLN closed at $3.58 after 18 trading sessions, down 8.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $3.5435 | $3.58 | $3.51 | $3.58 | 1.75K |
| Oct 29, 2026 | $3.74 | $3.74 | $3.5295 | $3.53 | 3.45K |
| Oct 28, 2026 | $3.795 | $3.795 | $3.71 | $3.711 | 1.76K |
| Oct 27, 2026 | $3.65 | $3.81 | $3.6032 | $3.81 | 1.9K |
| Oct 26, 2026 | $3.59 | $3.65 | $3.59 | $3.59 | 1.63K |
| Oct 23, 2026 | $3.74 | $3.76 | $3.64 | $3.67 | 4.31K |
| Oct 22, 2026 | $3.56 | $3.61 | $3.55 | $3.6092 | 3.52K |
| Oct 21, 2026 | $3.75 | $3.80 | $3.72 | $3.72 | 3.15K |
| Oct 20, 2026 | $3.67 | $3.71 | $3.67 | $3.70 | 2.62K |
| Oct 19, 2026 | $3.75 | $3.75 | $3.66 | $3.66 | 930 |
| Oct 16, 2026 | $3.71 | $3.71 | $3.56 | $3.56 | 680 |
| Oct 14, 2026 | $3.67 | $3.7038 | $3.52 | $3.65 | 3.3K |
| Oct 13, 2026 | $3.73 | $3.73 | $3.67 | $3.67 | 1.38K |
| Oct 12, 2026 | $3.79 | $3.80 | $3.55 | $3.79 | 3.37K |
| Oct 9, 2026 | $3.74 | $3.88 | $3.53 | $3.85 | 5.75K |
| Oct 7, 2026 | $3.81 | $3.81 | $3.81 | $3.81 | 386.24 |
| Oct 6, 2026 | $4.11 | $4.11 | $3.76 | $3.78 | 4.84K |
| Oct 5, 2026 | $3.92 | $3.92 | $3.92 | $3.92 | 757.24 |
The latest Smart Investors Daily articles mentioning MOLN.
Company
Market Activity
Research & News
MOLN research
Company profile and research snapshot.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD COWEN | Buy | — |
| Jul 7, 2026 | TD COWEN | Buy | — |
| Jul 6, 2026 | TD COWEN | Buy | — |
| Feb 2, 2026 | CLEAR STREET LLC | Buy | — |
| Feb 2, 2026 | TD COWEN | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 29, 2026
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.46) by 17.39 percent. This is a 76.97 percent increase over losses of $(1.65) per share
Yahoo · Oct 29, 2026
Dosing ongoing in fully recruited dose level 2 of MP0712 Phase 1/2a study; initial safety data to be presented at North America Conference on Lung Cancer in December 2026, efficacy data expected in 2027Emerging clinical data from lead Radio-DARPin candidate MP0712 enables strategic focus on radiopharmaceuticalsStreamlining of organization, in line with corporate focus, to advance Radio-DARPin programsCash position of CHF 57.5 million (USD ~69 million) as of September 30, 2026, expected to fund o
Yahoo · Oct 22, 2026
Attractive biodistribution supports selection of MP0730 as Radio-DARPin therapy candidate CD70 is a clinically validated target expressed in kidney cancer and other indicationsFirst-in-human program expected to start in H2 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics (“Molecular Partners” or the “Company”)
Benzinga · Aug 25, 2026
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.45) by 95.56 percent. This is a 31.34 percent decrease over losses of $(0.67) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MOLN.
